ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI Pharmaceuticals director Patrick D. Walsh reported selling Common Stock in two open-market transactions. On May 13, he sold 10,000 shares at an average price of $80.63 per share. On May 11, he sold an additional 3,973 shares at an average price of $80.75 per share. After these sales totaling 13,973 shares, Walsh directly holds 38,432 shares of ANI Pharmaceuticals Common Stock.
ANI Pharmaceuticals senior vice president Thomas Andrew Rowland reported an open-market sale of company stock. He sold 459 shares of Common Stock at $79.21 per share on May 12, 2026. After this transaction, he directly holds 38,271 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals President and CEO Nikhil Lalwani reported an open-market sale of 55,000 shares of Common Stock on May 11, 2026, at a weighted average price of $77.57 per share. The shares were sold in multiple trades at prices ranging from $76.21 to $80.38. Following this transaction, Lalwani directly holds 349,889 shares of ANI Pharmaceuticals Common Stock.
ANI Pharmaceuticals senior vice president of generics Ori Gutwerg reported an open-market sale of Common Stock. On May 12, 2026, he sold 2,772 shares at a price of $79.50 per share. After this transaction, he directly owns 78,696 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals Inc. senior vice president, general counsel and secretary Meredith Cook reported an open-market sale of 500 shares of common stock at $78.16 per share. The transaction occurred on May 13, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025.
After this sale, Cook directly holds 78,390 shares of ANI Pharmaceuticals common stock, indicating she retains a substantial equity position in the company despite the relatively small disposition.
ANI Pharmaceuticals furnished an updated investor presentation outlining strong growth plans and refreshed 2026 guidance. The company now projects $1.08–$1.14 billion in 2026 total net revenue, implying mid‑20% year-over-year growth, with its Rare Disease business expected to contribute about 60% of sales.
Lead asset Cortrophin Gel is forecast to generate $540–$575 million in 2026 revenue and approximately 60% growth, supported by expansion into acute gouty arthritis flares and other underpenetrated indications. ILUVIEN is guided to $78–$83 million, while Generics continue to provide strong cash flow.
For 2026, ANI targets adjusted non-GAAP EBITDA of $285–$300 million and adjusted non-GAAP diluted EPS of $9.19–$9.69. In Q1 2026, total net revenues reached $237.5 million and adjusted non-GAAP EBITDA was $63.0 million, reflecting solid top- and bottom-line growth. The board also authorized a $100 million share repurchase program, and the company reported cash of $311 million and net leverage of roughly 1.3x as of March 31, 2026.
ANIP affiliate submitted a Rule 144 notice to sell 55,000 shares of Common Stock on Nasdaq. The filing lists four planned issuances/allocations tied to performance shares and restricted stock dated 02/11/2026, 02/14/2026, and 03/07/2026. The cover line shows 55,000 shares, a value field of $4,266,563.58, and a reference figure of 22,734,618.
Patrick Walsh submitted a Form 144 notice to sell 3,973 shares of Common Stock. The filing lists the securities as restricted stock with an original grant date of 05/21/2025. The filing also reports that 6,000 shares were sold on 03/03/2026 for $445,390.20.
ANI Pharmaceuticals, Inc. reported strong results for the quarter ended March 31, 2026, with net revenues of $237.5 million, up from $197.1 million a year earlier. Net income rose to $29.5 million versus $15.7 million, driving diluted earnings per share to $1.28, compared with $0.69 in the prior-year period.
Growth was driven by Rare Disease and Brands, where net revenues increased to $128.2 million from $94.1 million, including $75.1 million from Cortrophin Gel and $19.3 million from ILUVIEN and YUTIQ. Generics and Other net revenues increased to $109.2 million from $103.0 million.
Operating income improved to $38.9 million from $26.2 million, helped by higher sales and a favorable contingent consideration fair value adjustment. Cash and cash equivalents grew to $311.2 million from $285.6 million at year-end, supported by $58.4 million of cash provided by operating activities, while total liabilities decreased modestly to $859.7 million from $899.7 million.